We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+17.47%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$3.02B
AUM Growth
+$399M
Cap. Flow
+$261M
Cap. Flow %
8.64%
Top 10 Hldgs %
52.67%
Holding
175
New
36
Increased
34
Reduced
22
Closed
43

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$50.4M
2
LJPC
La Jolla Pharmaceutical Company
LJPC
+$40.2M
3
MMSI icon
Merit Medical Systems
MMSI
+$32.5M
4
ABMD
Abiomed Inc
ABMD
+$30.5M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$24.6M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$57.5M
2
NXTM
NxStage Medical Inc.
NXTM
+$34.9M
3
TSRO
TESARO, Inc.
TSRO
+$25.4M
4
PBYI icon
Puma Biotechnology
PBYI
+$24.6M
5
AVXS
AveXis, Inc. Common Stock
AVXS
+$19.2M

Sector Composition

Rank Sector Weight
1 Healthcare 97.12%
2 Consumer Discretionary 0.06%
3 Technology 0.04%
4 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBIX icon
1
Neurocrine Biosciences
NBIX
$18.3B
$400M 13.25%
5,151,589
+360,000
+8% +$24.6M
FOLD
2
DELISTED
Amicus Therapeutics
FOLD
$257M 8.53%
17,888,597
– –
GBT
3
DELISTED
Global Blood Therapeutics, Inc.
GBT
$192M 6.38%
4,889,066
+625,000
+15% +$23.3M
ALNY icon
4
Alnylam Pharmaceuticals
ALNY
$38.1B
$169M 5.6%
1,330,802
-458,000
-26% -$57.5M
ZGNX
5
DELISTED
Zogenix, Inc.
ZGNX
$161M 5.33%
3,970,357
+300,000
+8% +$11.5M
LJPC
6
DELISTED
La Jolla Pharmaceutical Company
LJPC
$109M 3.61%
3,388,611
+1,231,600
+57% +$40.2M
BPMC
7
DELISTED
Blueprint Medicines
BPMC
$86M 2.85%
1,140,434
+715,773
+169% +$50.4M
ANAB icon
8
AnaptysBio
ANAB
$1.55B
$76.2M 2.53%
756,387
-225,882
-23% -$16.6M
PBYI icon
9
Puma Biotechnology
PBYI
$403M
$69.6M 2.31%
703,820
-220,000
-24% -$24.6M
XLRN
10
DELISTED
Acceleron Pharma
XLRN
$68.6M 2.27%
1,616,259
– –
TVTX icon
11
Travere Therapeutics
TVTX
$5.26B
$56.3M 1.87%
2,672,525
-13,679
-0.5% -$313K
CORI
12
DELISTED
Corium International, Inc.
CORI
$56.2M 1.86%
5,847,133
– –
AVXS
13
DELISTED
AveXis, Inc. Common Stock
AVXS
$53.1M 1.76%
480,141
-191,040
-28% -$19.2M
CTMX icon
14
CytomX Therapeutics
CTMX
$703M
$52.6M 1.74%
2,490,381
+1,100,000
+79% +$22.8M
DOVA
15
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
$52.1M 1.73%
1,809,015
+55,000
+3% +$1.51M
RGNX icon
16
Regenxbio
RGNX
$627M
$47.3M 1.57%
1,421,186
-20,000
-1% -$603K
VBIV
17
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$41.3M 1.37%
322,195
+103,334
+47% +$12.7M
ABMD
18
DELISTED
Abiomed Inc
ABMD
$40.3M 1.34%
215,000
+163,271
+316% +$30.5M
IOVA icon
19
Iovance Biotherapeutics
IOVA
$2.09B
$38.2M 1.27%
4,776,114
+50,000
+1% +$401K
MMSI icon
20
Merit Medical Systems
MMSI
$4.77B
$37.8M 1.25%
874,013
+774,013
+774% +$32.5M
ARGX icon
21
argenx
ARGX
$55.2B
$33.9M 1.12%
537,361
+87,361
+19% +$2.86M
ALBO
22
DELISTED
Albireo Pharma Inc
ALBO
$33.8M 1.12%
1,320,000
+475,000
+56% +$12M
TFX icon
23
Teleflex
TFX
$5.88B
$31.3M 1.04%
125,900
+70,700
+128% +$17.8M
MYOK
24
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$29.9M 0.99%
710,726
+160,009
+29% +$6.17M
QTNT
25
DELISTED
Quotient Limited Ordinary Shares
QTNT
$29.7M 0.98%
150,826
+57,651
+62% +$11.1M
1
2 3 4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q4 2017 Portfolio in Review

As of Q4 2017, Perceptive Advisors held 175 positions worth $3.02B, up 15% from $2.62B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Perceptive Advisors deployed $261M of net new capital in Q4 2017, opening 36 new positions and adding to 34 existing holdings. Its largest new stake was Zimmer Biomet: 206,000 shares worth $24.1M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $57.5M trimmed.

  • Perceptive Advisors's largest Q4 2017 buy was Zimmer Biomet: 206,000 shares worth $24.1M.
  • Perceptive Advisors added most to Blueprint Medicines in Q4 2017, an estimated $50.4M increase.
  • Perceptive Advisors's biggest Q4 2017 reduction was Alnylam Pharmaceuticals, cutting an estimated $57.5M.
  • Perceptive Advisors fully exited NxStage Medical Inc. in Q4 2017, selling an estimated $34.9M.
  • Perceptive Advisors's ten largest holdings make up 53% of its $3.02B portfolio in Q4 2017.
  • Perceptive Advisors opened 36 new positions and closed 43 in Q4 2017.
  • Perceptive Advisors's portfolio value rose 15% quarter-over-quarter to $3.02B.

Based on Perceptive Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.